Candriam S.C.A. Ultragenyx Pharmaceutical Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 713,092 shares of RARE stock, worth $32.4 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
713,092
Previous 688,942
3.51%
Holding current value
$32.4 Million
Previous $28.3 Million
39.9%
% of portfolio
0.23%
Previous 0.17%
Shares
18 transactions
Others Institutions Holding RARE
# of Institutions
326Shares Held
85.7MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$452 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$254 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$232 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$189 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$139 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.18B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...